builderall

CONFERENCE INFORMATION

Conference Description

This continuing pharmacy education program delivers up-to-date clinical evidence and best practices for the management of oral and intravenous specialty pharmacotherapies. The rapid expansion of therapeutic options, multiple lines of treatment, and advances in diagnostic precision medicine demand continuous, evidence-based education for pharmacists.

Participants will gain insights into the latest data and practice considerations across oncology, hematology, neurology, endocrinology, and weight management—particularly within diabetic populations. Expert faculty will also address evolving strategies for optimizing patient outcomes through adherence monitoring tools and pharmacist-led interventions.

The program further explores opportunities to enhance value and efficiency through the appropriate utilization of biosimilars, 505(b)(2) products, and other emerging modalities. Special attention will be given to the unique healthcare landscape in Puerto Rico, with discussion of collaborative strategies to improve patient access and drive system-wide value across stakeholders, including patients, specialty pharmacies, payers, and manufacturers.

Target Audience & Expected Attendance

This educational activity is designed for pharmacists and pharmacy technicians engaged in clinical practice, specialty pharmacy, managed care, and related fields who seek to enhance their knowledge of emerging specialty pharmacotherapies and patient management strategies.
Expected Attendance: approximately 200 participants.

Learner Objectives

Upon completion of this activity, learners will be able to:

  • Identify current and emerging specialty pharmacotherapy options and their clinical implications.

  • Discuss evidence-based strategies for therapy management, patient monitoring, and adherence optimization.

  • Apply pharmacist-led interventions to improve medication outcomes and patient safety.

  • Evaluate approaches to enhance practice efficiency, value-based care, and access to specialty therapies.